EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in ...
It is noteworthy that patients with mild TBI often report visual issues despite normal results of visual acuity measurements ...
More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant).
Researchers described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used ...
The authors searched PubMed, Scopus, MEDLINE, ScienceDirect, and ClinicalTrials.gov, and selected studies based on reports ...
Beacon Therapeutics presented 3-month interim safety and efficacy data from the Phase 2 DAWN trial of laru-zova (AGTC-501) for X-linked retinitis pigmentosa (XLRP) at the FLORetina ICOOR 2024 meeting ...
The acquisition creates a clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations.
DelveInsight has released a report entitled, “Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast-2034.″ This report is a detailed look at diabetic macular edema (DME) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback